Harmine Plus Exendin-4 Enhances Remission of Recent-Onset Type 1 Diabetes Following Anti-CD3 Therapy

Type 1 diabetes occurs when the immune system mistakenly destroys insulin-producing beta cells in the pancreas. Anti-CD3 therapy can help slow the disease's progression and preserve what remaining beta cells are left, but to truly reverse the condition, both the immune system needs to be managed and the beta cells need to regenerate.

The research team discovered that a combination of harmine and exendin-4, labeled H+E, can reduce inflammation-induced beta cell death, suppress harmful cytokine signals, and boost beta cell performance. While H+E treatment alone was not enough to reverse diabetes in mice with a recent onset of the disease, when combined with low-dose anti-CD3 therapy, it successfully normalized blood sugar levels, raised insulin production, improved glucose tolerance, expanded the beta cell population, and enhanced the remission of diabetes.

This improvement was attributed to a decrease in pro-inflammatory T-cell responses, an increase in regulatory T cells, and higher expression of exhaustion-related T-cell markers, all without causing widespread depletion of lymphocytes. The same immunomodulatory effects were observed in human blood cells. Through gene analysis, the researchers identified lncRNA SNHG6 as a crucial mediator of H+E action, as it shields beta cells from cytokine-induced stress, apoptosis, and immunogenicity.

In summary, the study shows that H+E treatment promotes the recovery and resilience of beta cells while decreasing their immunogenicity, allowing for the remission of recently diagnosed type 1 diabetes when used alongside anti-CD3 therapy. SNHG6 is identified as a new regulator of beta cell protection during inflammation.